ExCEEd Orphan Distribution d.o.o., a Croatia based fully-owned subsidiary of ExCEEd Orphan s.r.o., a company providing full business solutions for the treatment of rare diseases, signed an extension of exclusive Distribution Agreement with Advicenne, the specialty pharmaceutical company targeting patient needs in rare renal diseases, for the distribution and marketing of Sibnayal® in Estonia, Latvia and Lithuania.
Under the terms of the agreement, ExCEEd Orphan receives the exclusive rights to distribute and market Sibnayal® for the treatment of distal renal tubular acidosis (dRTA) in Estonia, Latvia and Lithuania. Sibnayal® received marketing authorisation in the European Union in May 2021 as the first and only label-approved drug for the treatment of Distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older.
About ExCEEd Orphan ExCEEd Orphan was founded in 2018 by five rare disease experts from multiple Central and Eastern European (CEE) countries. The Company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan includes products in therapeutic areas like haematology, neurology, immunology, and metabolic diseases.
For further information about ExCEEd Orphan, please visit www.exceedorphan.com